These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8980620)

  • 1. Immunohistochemistry (Ki-67 and p53) as a tool in determining malignancy in smooth muscle neoplasms (exemplified by a myxoid leiomyosarcoma of the uterus).
    Sprogøe-Jakobsen S; Hølund B
    APMIS; 1996 Oct; 104(10):705-8. PubMed ID: 8980620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
    Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
    Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
    Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
    Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
    Chen L; Yang B
    Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal p53 and p16 staining patterns distinguish uterine leiomyosarcoma from inflammatory myofibroblastic tumour.
    Schaefer IM; Hornick JL; Sholl LM; Quade BJ; Nucci MR; Parra-Herran C
    Histopathology; 2017 Jun; 70(7):1138-1146. PubMed ID: 28130839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma.
    Poncelet C; Walker F; Madelenat P; Bringuier AF; Scoazec JY; Feldmann G; Darai E
    Hum Pathol; 2001 Nov; 32(11):1190-6. PubMed ID: 11727257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
    Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
    Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas.
    Fernandez-Flores A; Monteagudo C
    Ann Diagn Pathol; 2016 Oct; 24():25-9. PubMed ID: 27649950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
    Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
    J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors.
    Gökaslan H; Türkeri L; Kavak ZN; Eren F; Sişmanoğlu A; Ilvan S; Durmuşoğlu F
    Gynecol Obstet Invest; 2005; 59(1):36-40. PubMed ID: 15377824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
    Mittal K; Demopoulos RI
    Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
    Amada S; Nakano H; Tsuneyoshi M
    Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma.
    Cornejo K; Shi M; Jiang Z
    Hum Pathol; 2012 Oct; 43(10):1567-72. PubMed ID: 22497850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
    Petrović D; Babić D; Forko JI; Martinac I
    Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sinonasal smooth muscle cell tumors: a clinicopathologic and immunohistochemical analysis of 12 cases with emphasis on the low-grade end of the spectrum.
    Huang HY; Antonescu CR
    Arch Pathol Lab Med; 2003 Mar; 127(3):297-304. PubMed ID: 12653572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
    Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
    Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The values of intratumoral mast cell count and Ki-67 immunoreactivity index in differential diagnosis of uterine smooth muscle neoplasms.
    Yavuz E; Güllüoğlu MG; Akbaş N; Tuzlali S; Ilhan R; Iplikçi A; Akhan SE
    Pathol Int; 2001 Dec; 51(12):938-41. PubMed ID: 11844066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
    Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
    Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].
    Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK
    Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.